Regina Krel, MD
Neurology · Hackensack, NJNPI 1053608257
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $160,608 of the $181,628 with a category attached, or 88.4%. AbbVie accounts for 68.8% of it on its own, with 33 other manufacturers making up the rest. Reporting peaked in 2021 at $59,858 and has fallen 54.5% since, to $27,225 in 2025. Among neurology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 787 payments — averaging $230.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$125K
- Biohaven Pharmaceuticals, Inc.$16K
- Biohaven Pharmaceutical Holding Company Ltd.$14K
- Teva Pharmaceuticals USA, Inc.$9K
- Pfizer$8K
- Lundbeck LLC$7K
- plus $3K from 28 others
Across 41 payments — averaging $424.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Teva Pharmaceuticals USA, Inc.$17K
What the payments were for
- Consulting fees$2,7792%
- Speaking & faculty fees$160,60888%
- Travel & lodging$4,5172%
- Food & beverage$13,7198%
- Education$60%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 359 | $124,932 |
| Biohaven Pharmaceuticals, Inc. | 33 | $15,552 |
| Biohaven Pharmaceutical Holding Company Ltd. | 23 | $13,792 |
| Teva Pharmaceuticals USA, Inc. | 73 | $8,510 |
| Pfizer | 42 | $8,326 |
| Lundbeck LLC | 41 | $7,074 |
| Lilly USA, LLC | 58 | $838 |
| Bristol Myers Squibb | 40 | $493 |
| Biogen | 21 | $368 |
| Novartis | 23 | $359 |
| TG Therapeutics, Inc. | 11 | $233 |
| Axsome Therapeutics, Inc. | 14 | $166 |
| E.r. Squibb & Sons, L.L.C. | 3 | $148 |
| SK Life Science, Inc. | 1 | $147 |
| EMD Serono, Inc. | 9 | $137 |
| Amgen | 5 | $90 |
| Currax Pharmaceuticals LLC | 5 | $73 |
| Johnson & Johnson | 4 | $61 |
| AstraZeneca(2 entities) | 3 | $47 |
| Genentech USA, Inc. | 3 | $43 |
| Sanofi | 2 | $33 |
| Philips North America LLC | 1 | $21 |
| Merz Pharmaceuticals, LLC | 1 | $19 |
| Supernus Pharmaceuticals, Inc. | 1 | $18 |
| Neurocrine Biosciences, Inc. | 1 | $17 |
| Scilex Pharmaceuticals Inc. | 1 | $17 |
| Mallinckrodt Enterprises LLC | 1 | $16 |
| Mallinckrodt Hospital Products Inc. | 1 | $16 |
| Bausch Health US, LLC | 1 | $15 |
| Collegium Pharmaceutical, Inc. | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| Assertio Therapeutics, Inc. | 1 | $14 |
| Zyla Life Sciences, Inc. | 1 | $14 |
| Impel Pharmaceuticals LLC | 2 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$181,628 in reported general payments places this provider in the 95th percentile of 521 neurology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 92 | $143,983 |
| UbrelvyUbrogepant | 65 | $91,579 |
| QuliptaAtogepant | 43 | $63,570 |
| Emgality PenGalcanezumab-Gnlm | 79 | $57,631 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 36 | $46,339 |
| ZavzpretZavegepant Hcl | 34 | $36,399 |
| Aimovig AutoinjectorErenumab-Aooe | 16 | $21,918 |
| Diclofenac Potassium | 15 | $6,874 |
| Candesartan Cilexetil | 42 | $4,846 |
| Gabapentin | 70 | $1,078 |
| Zolmitriptan OdtZolmitriptan | 11 | $942 |
| Topiramate | 37 | $394 |
| Lamotrigine | 24 | $379 |
| Sumatriptan Succinate | 30 | $377 |
| Eletriptan HbrEletriptan Hydrobromide | 17 | $282 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt, Zavzpret | $8,326 | $180,383126 claims |
| AbbVieUbrelvy, Qulipta | $124,932 | $155,149108 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 521 neurology providers in New Jersey.
Other neurology in Hackensack
- Mario VukicHackensack$310K
- Steven BromleyAudubon$1.5M
- Mary Ann PiconeTeaneck$1.5M
- Fiona GuptaOradell$1.1M
- Matthew DavisMiddletown$567K
- Amos KatzEatontown$558K
- Monte PellmarFreehold$429K
- Marcie RabinSummit$387K
- Ashish KapoorBayonne$329K
- Andrew SylvesterBridgewater$296K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.